Eisai (China) Listed for the Third Consecutive Year in China Top 100 Pharmaceutical Companies
Aug. 4, 2018, China Top 100 Pharmaceutical Enterprises List was released in the 35th China Pharmaceutical Industry Information Annual Conference 2018. Following the 97th place in 2015, and the 92nd place in 2016, Eisai (China) ranked 84th in the Top 100 List 2017.
Eisai China Holdings Ltd. ranked 84th in China Top 100 Pharmaceutical Enterprises List
With more than 20 years’ development, Eisai has established a development mode consisting of Eisai China Holdings Ltd. for capital control and management, while Eisai China Inc., Eisai (Liaoning) Pharmaceutical Co., Ltd. and Eisai (Suzhou) Trading Co., Ltd. for business support. Currently, the total registered capital of Eisai in China is USD108.54 million. Eisai China specializes in neurology, oncology and gastrointestinal areas, and expands to the generic business. The sales volume reached RMB3 billion yuan in 2017.
"Eisai China always keeps to the faith in providing drugs with high quality and reasonable price and addressing the diverse needs of patients and their families. As an important strategy of EWAY 2025, Eisai China will actively expand the market coverage including the low-tier market," said Ms. Yanhui Feng, Corporate Officer of Eisai Co. Ltd. and President of Eisai China Holdings Ltd. "Eisai China sticks, all the time, to the corporate philosophy that the interests of patients and their families are our priority and we will contribute to improving their well-beings, constantly bringing in high quality drugs, proactively expanding and innovating business mode, serving Chinese patients and their families."
China Pharmaceutical Industry Information Annual Conference is held by China National Pharmaceutical Industry Information Center. Based on the Annual Statistic Report of China Pharmaceutical Industry published by Ministry of Industry and Information Technology, China Top 100 Pharmaceutical Enterprises List reflects the status of China pharmaceutical industry, with the final data obtained through the first, second, third and fourth reviews in the materials of pharmaceutical enterprises. According to the data analysis, with the constant expansion of the industrial scale of China’s pharmaceutical industry, the threshold of the top 100 enterprises in China’s pharmaceutical industry has increased year by year, and the lowest threshold of the top 100 enterprises has increased from RMB2.4 billion yuan of main business income in 2016 to RMB2.56 billion yuan in 2017. The overall size of the top 100 companies has continued to grow rapidly.